Quick filters
- Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries Business Wire | Thursday August 2, 2012 8:30AM
- Gilead Sciences Announces Second Quarter 2012 Financial Results Business Wire | Thursday July 26, 2012 4:05PM
- Gilead's HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study Business Wire | Tuesday July 24, 2012 11:02AM
- Gilead's Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens Business Wire | Tuesday July 24, 2012 11:01AM
- Gilead's Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study Business Wire | Tuesday July 24, 2012 11:00AM
- Gilead Sciences to Release Second Quarter 2012 Financial Results on Thursday, July 26, 2012 Business Wire | Thursday July 19, 2012 4:30PM
- U.S. Food and Drug Administration Approves Gilead's Truvada® for Reducing the Risk of Acquiring HIV Business Wire | Monday July 16, 2012 12:45PM
- Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat Business Wire | Thursday June 28, 2012 4:30PM
- Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients Business Wire | Wednesday June 27, 2012 4:30PM
Live Discussion of GILD on StockTwits